π Medicare/Medicaid (MMM)
Federal lobbying activity for the medicare/medicaid issue area
AI Overview
Medicare/Medicaid (MMM) has attracted $1.4B in lobbying spending across 47.9K filings. This is a major lobbying issue area with significant corporate interest.
Spending by Year
Top Clients
| # | Client | Spending |
|---|---|---|
| 1 | American Health Care Association | $11.4M |
| 2 | Pharmaceutical Research and Manufacturers of America | $10.9M |
| 3 | PHRMA | $10.0M |
| 4 | American Hospital Association | $9.5M |
| 5 | Gilead Sciences, INC. | $7.7M |
| 6 | Omeros Corporation | $7.7M |
| 7 | Air Evac Lifeteam | $7.1M |
| 8 | Genentech | $7.0M |
| 9 | Novo Nordisk INC. | $6.8M |
| 10 | Blue Cross Blue Shield Association | $6.4M |
| 11 | Pharmaceutical Research and Manufacturers of America (PHRMA) | $6.1M |
| 12 | American Medical Association | $6.0M |
| 13 | Genentech, INC. | $5.9M |
| 14 | Fresenius Medical Care North America | $5.8M |
| 15 | America's Health Insurance Plans (Ahip) | $5.7M |
| 16 | Eli Lilly and Company | $5.7M |
| 17 | Amgen | $5.5M |
| 18 | Unitedhealth Group, INC. | $4.9M |
| 19 | Cigna Corporation | $4.9M |
| 20 | Emd Serono, INC. | $4.8M |
Top Lobbying Firms
| # | Firm | Revenue |
|---|---|---|
| 1 | Tarplin, Downs & Young, LLC | $89.9M |
| 2 | Mehlman Consulting, INC. | $48.3M |
| 3 | Tiber Creek Group | $41.0M |
| 4 | Alston & Bird LLP | $38.6M |
| 5 | Capitol Counsel LLC | $37.4M |
| 6 | Todd Strategy Group | $33.1M |
| 7 | Forbes-tate | $32.8M |
| 8 | Akin Gump Strauss Hauer & Feld | $32.8M |
| 9 | Avenue Solutions | $32.5M |
| 10 | The Mcmanus Group | $30.9M |
| 11 | The Nickles Group, LLC | $28.7M |
| 12 | Williams and Jensen, PLLC | $27.8M |
| 13 | Thorn Run Partners | $26.7M |
| 14 | Mcdermott+ LLC | $21.4M |
| 15 | Nvg, LLC | $18.4M |
| 16 | Capitol Hill Consulting Group | $18.3M |
| 17 | Liberty Partners Group, LLC | $18.0M |
| 18 | Red+blue Strategies | $17.9M |
| 19 | Farragut Partners LLP | $16.8M |
| 20 | Cornerstone Government Affairs, INC. | $16.6M |
Sample Lobbying Descriptions
β’Medicare physician payment and policy issues relating to cardiovascular and endovascular issues
β’allowing growth for hospitals with physician ownership
β’drug pricing, drug supply chain, opioid abuse epidemic, Medicare Part D
β’Dialysis vascular access services under Medicare
β’Funding opportunities for first responder products
β’Issues related to Medicare payment and reimbursement; provider nondiscrimination; scope of practice; and pain management issues.
β’Issues surrounding Medicare Dependent Hospitals Preserving Medicare reimbursement rates for rural public hospitals serving a disproportionate Medicare/Medcaid patient mix.
β’Issues related to hospital and other provider-related reimbursement, including: graduate medical education, value-based purchasing programs, post acute care, and inclusion of unique device identifiers
β’coverage and reimbursement, respiratory issues
β’Funding opportunities for first responder products.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.